patient reported having no direct contact with swine, but during the week before symptom onset had visited a farm where swine were present. The patient was not hospitalized and fully recovered. There was no evidence of human-to-human transmission.
Antigenic and Genetic Characterization of Influenza Viruses
The 93 public health laboratories participating as WHO collaborating laboratories in the United States are requested to submit a subset of their influenza virus-positive respiratory specimens to CDC for further characterization. CDC characterizes influenza viruses through one or more laboratory tests including genome sequencing, hemagglutination inhibition (HI), or neutralization assays. These data are used to monitor circulating influenza viruses for early identification of viruses that are antigenically different from the recommended influenza vaccine reference viruses. Most viruses analyzed are propagated in mammalian cell cultures because viruses propagated in tissue culture better represent viruses in circulation, and isolation rates of human influenza viruses are higher in mammalian cell cultures than in eggs, which is the matrix used for production of the majority of influenza vaccines (2, 3) . In addition, viruses are more likely to undergo adaptive changes when propagated in eggs. Antigenic and genetic characterization of circulating viruses is performed using both mammalian cell-and egg-propagated reference viruses.
Data obtained from antigenic characterization continue to play an important role in the assessment of the similarity between reference viruses and circulating viruses. Although vaccine effectiveness field studies must be conducted to determine how well the vaccine is working, these laboratory data are used to evaluate whether changes in the virus that could affect vaccine effectiveness might have occurred. Beginning with the 2014-15 season, a proportion of influenza A (H3N2) viruses have not yielded sufficient hemagglutination titers for antigenic characterization by HI. For nearly all viruses characterized at CDC laboratories, next generation sequencing is performed to determine the genetic identity of circulating viruses. For the subset of viruses that do not yield sufficient hemagglutination titers, antigenic properties are inferred using results obtained from viruses within the same genetic group as those that have been characterized antigenically.
Since October 1, 2015, CDC has antigenically or genetically characterized 483 viruses from the United States 
Antiviral Resistance of Influenza Viruses
Since October 4, 2015, a total of 699 influenza viruses (301 influenza A (H1N1)pdm09 viruses, 246 influenza A (H3N2) viruses, and 152 influenza B viruses) have been examined for antiviral resistance by the WHO Collaborating Center for Surveillance, Epidemiology, and Control of Influenza at CDC. All 152 influenza B viruses and 246 influenza A (H3N2) viruses tested were sensitive to oseltamivir and peramivir. Among 301 influenza A (H1N1)pdm09 viruses tested for resistance, two (0.7%) were found to be resistant to both oseltamivir and peramivir. All 301 influenza A (H1N1)pdm09 viruses tested were sensitive to zanamivir. High levels of resistance to the adamantanes (amantadine and rimantadine) persist among influenza A (H1N1)pdm09 and (H3N2) viruses. Adamantane drugs are not recommended for use against influenza at this time.
Outpatient Illness Surveillance
Since October 4, 2015, the weekly percentage of outpatient visits for influenza-like illness (ILI)** reported by approximately 2,000 U.S. Outpatient ILI Surveillance Network (ILINet) providers in 50 states, New York City, Chicago, the U.S. Virgin Islands, Puerto Rico, and the District of Columbia that constitute ILINet has ranged from 1.3%-2.5%. The percentage exceeded the national baseline † † of 2.1% for 2 consecutive weeks, from the week ending December 26, 2015-January 2, 2016 (weeks 51 and 52) ( Figure 2 ). The increase in percentage of patient visits for ILI during those 2 weeks might be influenced in part by a reduction in routine health care visits during the winter holiday season, as has occurred during previous influenza seasons. The percentage was at or above the national baseline for 4 consecutive weeks, from the week ending January 16, 2016-February 6, 2016 (weeks 2-5). During the 1997-1998 through 2014-15 influenza seasons, excluding the 2009 pandemic, peak weekly percentages of outpatient visits for ILI ranged from 2.4%-7.7% and remained above baseline levels for an average of 13 weeks (range = 1-19 weeks). For the week ending February 6, 2016 (week 5), the percentage of outpatient visits for ILI was 2.4%, and seven U.S. Department of Health and Human Services regions (1, 2, 3, 4, 6, 8, and 10) reported ILI activity at or above region-specific baseline levels.
Data collected in ILINet are used to produce a measure of ILI activity § § by jurisdiction. had insufficient data to report. ¶ A virus is considered "reference virus-like" if its hemagglutination inhibition (HI) or neutralization focus reduction (FRA) titer is within 4-fold of the homologous HI/FRA titer of the reference strain. A virus is considered as low to the reference virus if there is ≥8-fold or greater reduction in the HI or FRA titer when compared with the homologous HI or FRA titer of the reference strain. ** Defined as a fever ≥100°F (≥37.8°C), oral or equivalent, and cough and/or sore throat, without a known cause other than influenza. † † The national and regional baselines are the mean percentage of visits for ILI during noninfluenza weeks for the previous three seasons plus two standard deviations. Noninfluenza weeks are defined as periods of ≥2 consecutive weeks in which each week accounted for <2% of the season's total number of specimens that tested positive for influenza. National and regional percentages of patient visits for ILI are weighted on the basis of state population. Use of the national baseline for regional data is not appropriate. § § Activity levels are based on the percentage of outpatient visits in a jurisdiction attributed to ILI and are compared with the average percentage of ILI visits that occur during weeks with little or no influenza virus circulation. Activity levels range from minimal, corresponding to ILI activity from outpatient clinics at or below the average, to high, corresponding to ILI activity from outpatient clinics much higher than the average. , oral or equivalent, and cough and/or sore throat, without a known cause other than influenza. ¶ ¶ Levels of activity are 1) no activity; 2) sporadic: isolated laboratory-confirmed influenza cases or a laboratory-confirmed outbreak in one institution, with no increase in activity; 3) local: increased ILI, or two or more institutional outbreaks (ILI or laboratory-confirmed influenza) in one region of the state, with recent laboratory evidence of influenza in that region; virus activity no greater than sporadic in other regions; 4) regional: increased ILI activity or institutional outbreaks (ILI or laboratory-confirmed influenza) in more than two, but less than half of the regions in the state with recent laboratory evidence of influenza in those regions; and 5) widespread: increased ILI activity or institutional outbreaks (ILI or laboratory-confirmed influenza) in at least half the regions in the state, with recent laboratory evidence of influenza in the state.
widespread activity during each season has ranged from 20 in the 2011-12 season to 49 in the 2010-11 season. Complete medical chart abstraction data were available for 349 (39%) hospitalized patients with laboratory-confirmed influenza as of February 6, 2016. Among these, 91% of hospitalized adults had at least one underlying medical condition that placed them at high risk for influenza-associated complications. † † † The most commonly reported medical conditions were cardiovascular disease (39%), metabolic disorders (38%), and obesity (36%). Forty seven percent of hospitalized children had at least one underlying medical condition, the most commonly reported being asthma (19%) and neurologic disorders (17%). Among 29 hospitalized women of childbearing age (15-44 years), 7 (24%) were pregnant.
Influenza-Associated Hospitalizations

Pneumonia and Influenza-Associated Mortality
Pneumonia and influenza (P&I)-associated deaths are tracked through two systems, the National Center for Health Statistics (NCHS) Mortality Surveillance System, which reports the week the death occurred, and the 122 Cities Mortality Reporting System, which reports the week that the death certificate was registered. Because of these differences in reporting, the two data sources produce different percentages. Beginning with the 2015-16 influenza season, the NCHS Mortality Surveillance System has been the principal component of U.S. Mortality Surveillance System.
For the week ending January 23, 2016 (week 3), 6.9% (1,861 of 27,158) of all U.S. deaths were classified as resulting from P&I as reported by NCHS (Figure 3 ). This percentage is below the epidemic threshold of 7.6% for week 3. § § § Since October 4, 2015 the percentage of deaths attributable to P&I ranged from 6.2% to 7.2% and has not exceeded the epidemic *** FluSurv-NET conducts population-based surveillance for laboratoryconfirmed influenza-associated hospitalizations in children and adolescents aged <18 years (since the 2003-04 influenza season) and adults aged ≥18 years (since the 2005-06 influenza season threshold this season. During the past five influenza seasons, peak weekly percentages of deaths attributable to P&I have ranged from 8.7% during the 2011-12 season to 11.1% during the 2012-13 season. Since October 4, 2015, the weekly percentage of deaths attributed to P&I as reported in the 122 Cities Mortality Reporting System has not exceeded the epidemic threshold for ≥2 weeks, ranging from 5.2%-7.7%. For the week ending February 6, 2016 (week 5), the weekly percentage of deaths attributable to P&I was 6.2%, below the epidemic threshold of 6.9% for week 5. During the past five influenza seasons, peak weekly percentages of deaths attributable to P&I have ranged from 7.8% during the 2011-12 season to 9.9% during the 2012-13 season. 
Influenza-Associated Pediatric Mortality
As of February 6, 2016 (week 5), 11 influenza-associated pediatric deaths that occurred during the 2015-16 season have been reported to CDC. Of these, one death was associated with an influenza A (H3N2) virus, three were associated with an influenza A (H1N1)pdm09 virus, three were associated with an influenza A virus for which no subtyping was performed, and four were associated with an influenza B virus. Since influenza-associated pediatric mortality became nationally notifiable in 2004, the total number of influenza-associated pediatric deaths has ranged from 37-171 per season, excluding the 2009 pandemic, during which 358 pediatric deaths were reported to CDC during April 15, 2009-October 2, 2010.
Summary
What is already known about this topic? CDC collects, compiles, and analyzes data on influenza activity year-round in the United States. Timing of influenza activity and predominant circulating influenza viruses vary by season.
What is added by this report? Influenza activity remained low in the United States through early December and began to increase slowly in mid-December. Influenza A and B viruses have been reported. Influenza A (H3N2) viruses predominated from October to mid-December, and influenza A (H1N1)pdm09 viruses have predominated from mid-December to February. To date, the majority of influenza viruses that have been antigenically or genetically characterized are similar to components of the 2015-16 Northern Hemisphere vaccine.
What are the implications for public health practice?
Vaccination is the primary method to prevent influenza illness and its complications. Health care providers should continue to recommend influenza vaccination to all unvaccinated persons aged ≥6 months now and throughout the influenza season. As an adjunct to vaccine, treatment with influenza antiviral medications is recommended for patients with confirmed or suspected influenza who have severe, complicated, or progressive illness; who require hospitalization; or who are at high risk for influenza-related complications. Antivirals can lessen severity and duration of illness and can reduce severe outcomes of influenza. Antiviral medications work best when administered early in the course of influenza-like illness.
